Breast Cancer Drugs Market By Therapy (Chemotherapy, Hormonal therapy, Targeted therapy, Immunotherapy), By Age group (Below 55 years, Above 55 years), By Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
The breast cancer drugs market valued for $26.4 billion in 2022 and is estimated to reach $59.3 billion by 2032, exhibiting a CAGR of 8.4% from 2023 to 2032.
Breast cancer is a type of cancer that develops in the breast tissue. It occurs when the cells in the breast grow and divide uncontrollably, forming a tumor. These tumors can be malignant (cancerous) or benign (non-cancerous). It predominantly occurs in women, however, it can also occur in men, although it is relatively rare. It can originate in different parts of the breast, such as the milk ducts, the lobules (which produce milk), or the connective tissue. The most common type of breast cancer occurs in the milk ducts and is known as ductal carcinoma, while cancer originating in the lobules is called lobular carcinoma. Moreover, the treatment for breast cancer involves a combination of different approaches, including chemotherapy, targeted therapy, and hormone therapy. Each treatment modality serves a specific purpose in managing and combating breast cancer, and the selection of treatment depends on various factors, such as the stage & type of breast cancer, the presence of specific receptors, and the patient's overall health & preferences.
The major factors that drive the growth of breast cancer drugs market are rise in prevalence of breast cancer, advancements in diagnostic techniques, and increase in awareness about breast cancer and available treatment options. It is a significant global health concern, impacting millions of women worldwide. The incidence of breast cancer has been steadily rising over the years, making it one of the most prevalent cancers among women. For instance, according to World Health Organization (WHO) 2021, about 2.3 million women were diagnosed with breast cancer globally in 2020, thus rise in prevalence of breast cancer is expected to fuel the growth of market. In addition, early detection and diagnosis are vital in improving the prognosis of breast cancer. Regular breast self-examinations, clinical breast examinations, and mammography screenings can help detect breast cancer in its early stages when treatment is most effective. Thus, advancements in diagnostic techniques for early detection of breast cancer is anticipated to boost the growth of the market.
Furthermore, with rise in incidence of breast cancer cases, there is an upsurge in focus on improving treatment options for breast cancer patients. The objective is to develop drugs that not only enhance survival rates, however, also minimize side effects and improve the quality of life for patients. This drive for better treatment options encourages pharmaceutical companies and researchers to invest in the development of more effective and well-tolerated drugs to treat breast cancer and drive the market growth. Furthermore, growing awareness about breast cancer, its risk factors, and the importance of regular screenings have led to an increase in the number of women undergoing breast cancer screening. In addition, government initiatives, non-profit organizations, and healthcare campaigns have played a crucial role in raising awareness and encourage women to undergo regular mammograms and clinical examinations. Increased screening rates drive early diagnosis and subsequently lead to surge in demand for breast cancer drugs, thus propelling the market growth.
However, factor such as side effects associated with drugs is anticipated to restrain the growth of market. Many breast cancer drugs have associated side effects and toxicities that can affect patients’ quality of life. For instance, chemotherapy is known for causing side effects such as hair loss, nausea, fatigue, and immunosuppression, thereby hindering market growth. Moreover, rise in demand for novel therapeutics for treating breast cancer, increase in R&D activities for development of new and more effective drugs, and rise in regulatory approvals for anticancer drugs are expected to offer lucrative opportunities to key players of breast cancer drugs market.
The breast cancer drugs market is segmented on the basis of therapy, age group, distribution channel, and region. On the basis of therapy, the market is categorized into chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. On the basis of age group, the market is bifurcated into below 55 years and above 55 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major Key players that operate in the global breast cancer drugs market are Gilead Sciences, Inc., Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd. The key players have adopted strategies such as acquisition, funding, product launch, and product approval to expand their product portfolio.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the breast cancer drugs market analysis from 2022 to 2032 to identify the prevailing breast cancer drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the breast cancer drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global breast cancer drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapy
Chemotherapy
Hormonal therapy
Targeted therapy
Immunotherapy
By Age group
Below 55 years
Above 55 years
By Distribution channel
Hospital Pharmacies
Drug Store and Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Merck & Co., Inc.
Zydus Lifesciences Limited
Gilead Sciences, Inc.
Novartis AG
Eli Lilly and Company
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of breast cancer
- 3.4.1.2. Advancements in diagnostic technologies
- 3.4.1.3. High investments in research and development
- 3.4.2. Restraints
- 3.4.2.1. Adverse effects associated with the use cancer drugs
- 3.4.3. Opportunities
- 3.4.3.1. High growth potential in untapped emerging economies
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: BREAST CANCER DRUGS MARKET, BY THERAPY
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Chemotherapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Hormonal therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Targeted therapy
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Immunotherapy
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- CHAPTER 5: BREAST CANCER DRUGS MARKET, BY AGE GROUP
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Below 55 years
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Above 55 years
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Drug Store and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: BREAST CANCER DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Therapy
- 7.2.3. Market size and forecast, by Age group
- 7.2.4. Market size and forecast, by Distribution channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Therapy
- 7.2.5.1.3. Market size and forecast, by Age group
- 7.2.5.1.4. Market size and forecast, by Distribution channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Therapy
- 7.2.5.2.3. Market size and forecast, by Age group
- 7.2.5.2.4. Market size and forecast, by Distribution channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Therapy
- 7.2.5.3.3. Market size and forecast, by Age group
- 7.2.5.3.4. Market size and forecast, by Distribution channel
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Therapy
- 7.3.3. Market size and forecast, by Age group
- 7.3.4. Market size and forecast, by Distribution channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Therapy
- 7.3.5.1.3. Market size and forecast, by Age group
- 7.3.5.1.4. Market size and forecast, by Distribution channel
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Therapy
- 7.3.5.2.3. Market size and forecast, by Age group
- 7.3.5.2.4. Market size and forecast, by Distribution channel
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Therapy
- 7.3.5.3.3. Market size and forecast, by Age group
- 7.3.5.3.4. Market size and forecast, by Distribution channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Therapy
- 7.3.5.4.3. Market size and forecast, by Age group
- 7.3.5.4.4. Market size and forecast, by Distribution channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Therapy
- 7.3.5.5.3. Market size and forecast, by Age group
- 7.3.5.5.4. Market size and forecast, by Distribution channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Therapy
- 7.3.5.6.3. Market size and forecast, by Age group
- 7.3.5.6.4. Market size and forecast, by Distribution channel
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Therapy
- 7.4.3. Market size and forecast, by Age group
- 7.4.4. Market size and forecast, by Distribution channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Therapy
- 7.4.5.1.3. Market size and forecast, by Age group
- 7.4.5.1.4. Market size and forecast, by Distribution channel
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Therapy
- 7.4.5.2.3. Market size and forecast, by Age group
- 7.4.5.2.4. Market size and forecast, by Distribution channel
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Therapy
- 7.4.5.3.3. Market size and forecast, by Age group
- 7.4.5.3.4. Market size and forecast, by Distribution channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Therapy
- 7.4.5.4.3. Market size and forecast, by Age group
- 7.4.5.4.4. Market size and forecast, by Distribution channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Therapy
- 7.4.5.5.3. Market size and forecast, by Age group
- 7.4.5.5.4. Market size and forecast, by Distribution channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Therapy
- 7.4.5.6.3. Market size and forecast, by Age group
- 7.4.5.6.4. Market size and forecast, by Distribution channel
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Therapy
- 7.5.3. Market size and forecast, by Age group
- 7.5.4. Market size and forecast, by Distribution channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Therapy
- 7.5.5.1.3. Market size and forecast, by Age group
- 7.5.5.1.4. Market size and forecast, by Distribution channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Therapy
- 7.5.5.2.3. Market size and forecast, by Age group
- 7.5.5.2.4. Market size and forecast, by Distribution channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Therapy
- 7.5.5.3.3. Market size and forecast, by Age group
- 7.5.5.3.4. Market size and forecast, by Distribution channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Therapy
- 7.5.5.4.3. Market size and forecast, by Age group
- 7.5.5.4.4. Market size and forecast, by Distribution channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Novartis AG
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Pfizer Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. AstraZeneca plc
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Eli Lilly and Company
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Merck & Co., Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Bristol-Myers Squibb Company
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.7. Zydus Lifesciences Limited
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Teva Pharmaceutical Industries Ltd.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. F. Hoffmann-La Roche Ltd.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Gilead Sciences, Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. GLOBAL BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 02. BREAST CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. BREAST CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. BREAST CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. BREAST CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 07. BREAST CANCER DRUGS MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. BREAST CANCER DRUGS MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
- TABLE 09. GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 10. BREAST CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. BREAST CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. BREAST CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. BREAST CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 17. NORTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 18. U.S. BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 19. U.S. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 20. U.S. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 21. CANADA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 22. CANADA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 23. CANADA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 24. MEXICO BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 25. MEXICO BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 26. MEXICO BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 27. EUROPE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 28. EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 29. EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 30. EUROPE BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 31. GERMANY BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 32. GERMANY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 33. GERMANY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 34. FRANCE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 35. FRANCE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 36. FRANCE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 37. UK BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 38. UK BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 39. UK BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 40. ITALY BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 41. ITALY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 42. ITALY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 43. SPAIN BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 44. SPAIN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 45. SPAIN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 47. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 48. REST OF EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 52. ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 53. JAPAN BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 54. JAPAN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 55. JAPAN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 56. CHINA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 57. CHINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 58. CHINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 59. INDIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 60. INDIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 61. INDIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 64. AUSTRALIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 66. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 67. SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 71. LAMEA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 72. LAMEA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 73. LAMEA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 74. LAMEA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 75. BRAZIL BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 76. BRAZIL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 77. BRAZIL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 78. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 79. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 80. SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 81. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 82. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 83. SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 84. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
- TABLE 85. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
- TABLE 86. REST OF LAMEA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
- TABLE 87. NOVARTIS AG: KEY EXECUTIVES
- TABLE 88. NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 89. NOVARTIS AG: PRODUCT SEGMENTS
- TABLE 90. NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 91. NOVARTIS AG: KEY STRATERGIES
- TABLE 92. PFIZER INC.: KEY EXECUTIVES
- TABLE 93. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 94. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 95. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 96. ASTRAZENECA PLC: KEY EXECUTIVES
- TABLE 97. ASTRAZENECA PLC: COMPANY SNAPSHOT
- TABLE 98. ASTRAZENECA PLC: PRODUCT SEGMENTS
- TABLE 99. ASTRAZENECA PLC: PRODUCT PORTFOLIO
- TABLE 100. ASTRAZENECA PLC: KEY STRATERGIES
- TABLE 101. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 102. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 103. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
- TABLE 104. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 105. ELI LILLY AND COMPANY: KEY STRATERGIES
- TABLE 106. MERCK & CO., INC.: KEY EXECUTIVES
- TABLE 107. MERCK & CO., INC.: COMPANY SNAPSHOT
- TABLE 108. MERCK & CO., INC.: PRODUCT SEGMENTS
- TABLE 109. MERCK & CO., INC.: PRODUCT PORTFOLIO
- TABLE 110. MERCK & CO., INC.: KEY STRATERGIES
- TABLE 111. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
- TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
- TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
- TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
- TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
- TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
- TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
- TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
- TABLE 119. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES
- TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
- TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 126. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 127. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 129. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 130. GILEAD SCIENCES, INC.: KEY EXECUTIVES
- TABLE 131. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 132. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
- TABLE 133. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 134. GILEAD SCIENCES, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. BREAST CANCER DRUGS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF BREAST CANCER DRUGS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN BREAST CANCER DRUGS MARKET (2023-2032)
- FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 05. LOW BARGAINING POWER OF BUYERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALBREAST CANCER DRUGS MARKET
- FIGURE 10. BREAST CANCER DRUGS MARKET, BY THERAPY, 2022(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2022(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BREAST CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. BREAST CANCER DRUGS MARKET BY REGION, 2022
- FIGURE 23. U.S. BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 24. CANADA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 25. MEXICO BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 26. GERMANY BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 27. FRANCE BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 28. UK BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 29. ITALY BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 30. SPAIN BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 31. REST OF EUROPE BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 32. JAPAN BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 33. CHINA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 34. INDIA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 35. AUSTRALIA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 36. SOUTH KOREA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 37. REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 38. BRAZIL BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 39. SAUDI ARABIA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SOUTH AFRICA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 41. REST OF LAMEA BREAST CANCER DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 46. COMPETITIVE DASHBOARD
- FIGURE 47. COMPETITIVE HEATMAP: BREAST CANCER DRUGS MARKET
- FIGURE 48. TOP PLAYER POSITIONING, 2022
- FIGURE 49. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 50. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 51. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 52. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 53. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 54. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
- FIGURE 56. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 58. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 59. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 60. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 61. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 62. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
- FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 64. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 65. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 66. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 69. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 70. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 71. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 72. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 73. GILEAD SCIENCES, INC.: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook